Clinical Trial Update: An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial of PT-112 Injection in patients with advanced solid tumors and advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Solid Tumors

Drugs mentioned

• PT-112 Injection (PT-112)

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN